Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 14;14:4201. doi: 10.1038/s41467-023-40012-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a–c Plasma from 97 PASC patients was screened for reactivity against SARS-CoV-2. a Serological reactivity against the spike receptor binding domain in inflPASC and niPASC patients, by isotype, with means displayed (red). b Serological reactivity against nucleocapsid in inflPASC and niPASC patients, by isotype, with means displayed (red). c Serological anti-nucleocapsid responses in patients in inflPASC and niPASC cohorts more than 120 days DPSO with means displayed (red). d Normalized abundance of indicated proteins with means displayed (red). e–g Plasma from 96 PASC patients with mixed symptomology were screened by Exagen clinical laboratory for reactivity against 30 clinically relevant autoantigens. e Heatmap of patient results. Each column represents a single patient grouped by the total number of autoreactive positive tests that the patient displayed. Bolded boxes represent clinical positive tests with the color indicating the magnitude of the test result. Scale for each test is documented below the heatmap. f ANA titers in niPASC and inflPASC patients. g Total positive autoreactive tests in niPASC and inflPASC patients. h Trend in ANA titers in (n = 7) niPASC and (n = 8) inflPASC patients 1 year after initial plasma collection and screening. a–c Two-tailed unpaired T testing. d One-way ANOVA with multiple comparisons. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.